Named on one round in the feed.
Since 2026-09-30
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Astrocyte Pharmaceuticals A clinical-stage biotechnology company developing first-in-class cerebroprotective therapies for concussion, traumatic brain injury (TBI) and stroke | Series B Verified against 4 of 9 sources | $9.5M | 2026-09-30 | [ PART ] |